|本期目录/Table of Contents|

[1]徐双喜,杨玉坤,姜海波.重症肺炎HE4表达水平及预后分析[J].中华肺部疾病杂志,2024,(02):300-302.[doi:10.3877/cma.j.issn.1674-6902.2024.02.028]
点击复制

重症肺炎HE4表达水平及预后分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年02期
页码:
300-302
栏目:
短篇论著
出版日期:
2024-04-20

文章信息/Info

Title:
-
作者:
徐双喜1; 杨玉坤3; 姜海波2
231500 庐江,安徽省庐江县人民医院输血科1、呼吸与危重症医学科一病区2
230000 合肥,合肥诺森医学检验有限公司3
Author(s):
-
关键词:
重症肺炎;  人附睾蛋白4;  预后
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2024.02.028
摘要:
-
Abstract:
-

参考文献/References:

1 Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients[J]. BMJ, 2021, 375: e065871.
2 Baek MS, Park S, Choi JH, et al. Mortality and prognostic prediction in very elderly patients with severe pneumonia[J]. J Intensive Care Med, 2020, 35(12): 1405-1410.
3 Bateman RM, Sharpe MD, Jagger JE, et al. 36th international symposium on intensive care and emergency medicine: Brussels, Belgium. 15-18 March 2016[J]. Crit Care, 2016, 20(Suppl 2): 94.
4 Kesmez Can F, Özkurt Z, Öztürk N, et al. Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection[J]. Int J Clin Pract, 2021, 75(12): e14970.
5 Sayah W, Berkane I, Guermache I, et al. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19[J]. Cytokine, 2021, 141: 155428.
6 Zhang LS, Ling PY, Chen Y, et al. [Progress in the effect of human epididymis protein 4 on sperm maturation][J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2022, 56(8): 1123-1126.
7 Huang X, Guo X, Yan G, et al. Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1α/HE4/NF-κB Pathway[J]. J Cardiovasc Pharmacol, 2022, 79(6): 904-913.
8 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学, 2016, 36(2): 11.
9 Ferreira-Coimbra J, Tejada S, Campogiani L, et al. Levels of evidence supporting European and American community-acquired pneumonia guidelines[J]. Eur J Clin Microbiol Infect Dis, 2020, 39(6): 1159-1167.
10 Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study[J]. Lancet Infect Dis, 2016, 16(3): 339-347.
11 Ren Q, Liu H, Wang Y, et al. The role of red blood cell distribution width in the severity and prognosis of community-acquired pneumonia[J]. Can Respir J, 2021, 2021: 8024024.
12 Song Y, Yang J, Sun H, et al. Serum levels of sirtuin 6 are associated with severe community acquired pneumonia in children: An observational study[J]. Cir Cir, 2022, 90(5): 632-637.
13 Kühnapfel A, Horn K, Klotz U, et al. Genetic regulation of cytokine response in patients with acute community-acquired pneumonia[J]. Genes(Basel), 2022, 13(1): 111.
14 陈晓珊. 血清PCT、RAGE、sTREM-1表达水平与重症肺炎患者病情严重程度及预后的关系[J]. 标记免疫分析与临床, 2020, 27(1): 136-141.
15 Sun ML, Yang ZY, Wu QJ, et al. The role of human epididymis protein 4 in the diagnosis and prognosis of diseases: An umbrella review of systematic reviews and Meta-analyses of observational studies[J]. Front Med(Lausanne), 2022, 9: 842002.
16 Sütö R, Pócsi M, Szabó Z, et al. Elevated level of serum human epididymis protein 4(HE4)predicts disease severity and mortality in COVID-19 pneumonia[J]. BMC Pulm Med, 2023, 23(1): 512.
17 Wang J, Zhao H, Xu F, et al. Human epididymis protein 4(HE4)protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling[J]. Genes Genomics, 2019, 41(9): 1045-1053.
18 Luo J, Liang J, Wang S, et al. Serum human epididymis secretory protein 4 correlates with sepsis-associated acute respiratory distress syndrome and 28-day mortality in critically ill patients[J]. Ann Clin Biochem, 2022, 59(5): 338-346.
19 Raghu G, Richeldi L, Jagerschmidt A, et al. Idiopathic pulmonary fibrosis: Prospective, case-controlled study of natural history and circulating biomarkers[J]. Chest, 2018, 154(6): 1359-1370.
20 Saleem N, Kulkarni A, Snow T, et al. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: A systematic review, Meta-analysis, and Meta-regression of randomized control trials[J]. Chest, 2023, 163(3): 484-497.
21 Zhang C, He H, Chen X, et al. The prediction of lymphocyte count and neutrophil count on the efficacy of Xuebijing adjuvant treatment for severe community-acquired pneumonia: A post hoc analysis of a randomized controlled trial[J]. Phytomedicine, 2023, 110: 154614.
22 Ge YL, Zhang HF, Zhang Q, et al. Neutrophil-to-lymphocyte ratio in adult community-acquired pneumonia patients correlates with unfavorable clinical outcomes[J]. Clin Lab, 2019, 65(5): doi: 10.7754/Clin.Lab.2018.181042.
23 Kuikel S, Pathak N, Poudel S, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review[J]. Health Sci Rep, 2022, 5(3): e630.
24 马晓迪, 刘振宁. 中性粒细胞/淋巴细胞比值对重症急性胰腺炎病情严重程度及预后评估价值的研究进展[J]. 中国实用内科杂志, 2023, 43(6): 518-521.
25 Meng Y, Zhang L, Huang M, et al. Blood heparin-binding protein and neutrophil-to-lymphocyte ratio as indicators of the severity and prognosis of community-acquired pneumonia[J]. Respir Med, 2023, 208: 107144.
26 Xiao X, Hong Y, Wang S, et al. Diagnostic value of plasma heparin-binding protein and the heparin-binding protein-to-albumin ratio in patients with community-acquired Pneumonia: a retrospective study[J]. BMC Infect Dis, 2023, 23(1): 777.
27 刘晓燕, 张小佛, 李 嘉, 等. 肝素结合蛋白对儿童重症腺病毒肺炎的诊断价值[J]. 中国当代儿科杂志, 2022, 24(9): 1014-1019.

备注/Memo

备注/Memo:
通信作者: 姜海波, Email: jianghaibo2004@126.com
更新日期/Last Update: 2024-04-20